CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults
Main Authors: | Beveridge, N, Minassian, A, Rowland, R, Poulton, I, Satti, I, Harris, S, Poyntz, H, Hamill, M, Griffiths, K, Sander, C, Ambrozak, D, Price, D, Hill, B, Casazza, J, Douek, D, Koup, R, Roederer, M, Winston, A, Ross, J, Sherrad, J, Rooney, G, Williams, N, Lawrie, A, Fletcher, H, Pathan, A |
---|---|
Format: | Conference item |
Published: |
2011
|
Similar Items
-
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
by: Minassian, A, et al.
Published: (2011) -
A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
by: Rowland, R, et al.
Published: (2012) -
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
by: Beveridge, N, et al.
Published: (2007) -
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
by: Rowland, R, et al.
Published: (2013) -
Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
by: Harris, S, et al.
Published: (2011)